News coverage about BioDelivery Sciences International (NASDAQ:BDSI) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioDelivery Sciences International earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.8582097917292 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- -$0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter (americanbankingnews.com)
- Financial Comparison: BioDelivery Sciences International (BDSI) and Patheon (PTHN) (americanbankingnews.com)
- BioDelivery Sciences International, Inc. (BDSI) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- BioDelivery Sciences International, Inc., (NASDAQ: BDSI),Xperi Corporation, (NASDAQ: XPER), The Ultimate Software … – Hot Stocks In Focus (press release) (reagentsglobalmarket.com)
- BDSI CEO on big formulary add (bizjournals.com)
Several research firms recently commented on BDSI. HC Wainwright set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, August 10th. Piper Jaffray Companies set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.50 price target on shares of BioDelivery Sciences International in a research report on Monday, August 14th. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Roth Capital set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $4.29.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a return on equity of 33.83% and a net margin of 10.40%. The company had revenue of $11.25 million during the quarter, compared to analyst estimates of $9.40 million. During the same quarter last year, the business posted ($0.30) earnings per share. The firm’s revenue was up 215.1% on a year-over-year basis. equities analysts predict that BioDelivery Sciences International will post 0.16 EPS for the current fiscal year.
In other BioDelivery Sciences International news, CEO Mark A. Sirgo sold 65,405 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $2.75, for a total transaction of $179,863.75. Following the completion of the transaction, the chief executive officer now owns 1,509,262 shares in the company, valued at $4,150,470.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mark A. Sirgo sold 54,833 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $2.90, for a total value of $159,015.70. Following the transaction, the chief executive officer now owns 1,509,262 shares of the company’s stock, valued at approximately $4,376,859.80. The disclosure for this sale can be found here. Insiders have sold 402,127 shares of company stock valued at $1,142,798 in the last 90 days. Company insiders own 7.73% of the company’s stock.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
What are top analysts saying about BioDelivery Sciences International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioDelivery Sciences International Inc. and related companies.